Brief: CytRx announces positive interim phase 2 aldoxorubicin results in glioblastoma multiforme
06/01/2015 11:00
Jan 6 (Reuters) - CytRx Corp CYTR.O : * Announces positive interim phase 2 aldoxorubicin results in glioblastoma multiforme (brain cancer) * Says novel albumin-binding drug candidate appears to allow doxorubicin to cross the tumor's blood-brain barrier in humans * Says aldoxorubicin shows a complete response, tumor shrinkage, prolonged stable disease, and favorable tolerability in patients * Source text for Eikon ID:nPn7J7x8f * Further company coverage CYTR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C